Safety, Tolerability,and Adherence to Co-formulated Tenofovir-emtricitabine-rilpivirine Used as HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men.

Exclusion Criteria

• •6. Non-sexual exposure
• •7. Exposure occurring during sex between a man and a woman
• •8. HIV infection diagnosed on day 1 serological testing including indeterminate serology consistent with possible primary HIV infection
• •9. Use of any medication contraindicated with FTC-RPV-TDF
• •10. Serum hepatic transaminase (alanine aminotransferase \[ALT\] greater than 5 times the upper limit of the normal range
• •11. Serum estimated Glomerular Filtration Rate (eGFR) \<60mL/min/ BSAc
• •12. Current therapy for hepatitis B
• •13. Day 1 serological evidence of chronic/active hepatitis B
• •14. Previous NPEP containing FTC-RPV-TDF
• •15. A patient with a history or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study, or interfere with the patient's participation for the full duration of the study